Table 5 Baseline predictors of hip fractures in the full RA cohort*

Age, per 10 years

5.02

(3.23; 7.82)

NA

2.51

(2.09; 3.03)

NA

2.85

(2.39; 3.40)

NA

RA duration, per 10 years

1.64

(1.29; 2.08)

1.23

(0.99; 1.54)

NA¹

NA¹

1.27

(1.12; 1.43)

1.08

(0.96; 1.21)

RF-positive

1.33

(0.51; 3.50)

2.59

(0.98; 6.88)

NA¹

NA¹

1.18

(0.77; 1.82)

1.55

(1.01; 2.39)

HAQ, per SD

1.72

(1.18; 2.51)

1.38

(0.93; 2.06)

1.29

(1.05; 1.59)

1.03

(0.84; 1.27)

1.40

(1.17; 1.67)

1.13

(0.94; 1.34)

VAS pain, per SD

1.14

(0.79; 1.65)

1.26

(0.87; 1.81)

1.10

(0.90; 1.34)

1.03

(0.84; 1.25)

1.12

(0.94; 1.34)

1.09

(0.92; 1.30)

VAS global health, per SD

1.46

(1.01; 2.12)

1.63

(1.13; 2.36)

1.20

(0.99; 1.47)

1.09

(0.89; 1.33)

1.27

(1.07; 1.52)

1.20

(1.00; 1.43)

Methotrexate

0.26

(0.10; 0.69)

0.49

(0.18; 1.33)

0.70

(0.47; 1.04)

0.78

(0.52; 1.16)

NA¹

NA¹

bDMARDs

0.33

(0.05; 2.45)

1.23

(0.16; 9.49)

0.18

(0.04; 0.73)

0.42

(0.10; 1.71)

0.21

(0.07; 0.66)

0.52

(0.16; 1.66)

Prednisolone

1.94

(0.90; 4.19)

2.21

(0.99; 4.94)

1.54

(1.02; 2.32)

1.19

(0.79; 1.81)

1.62

(1.12; 2.32)

1.30

(0.90; 1.87)